Literature DB >> 3103412

Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure.

N Sharpe, R Coxon, M Webster, R Luke.   

Abstract

The hemodynamic effects of intermittent and continuous treatment with transdermal nitroglycerin, 10 mg/24 hours, were compared in 10 patients with chronic congestive heart failure (CHF). Eight patients responded to initial application with more than a 20% reduction in mean pulmonary artery wedge pressure. Cardiac index increased from a control value of 2.1 +/- 0.5 to 2.4 +/- 0.6 liters/min/m2 at 2 hours (p less than 0.05) and mean pulmonary wedge pressure was reduced from 22 +/- 5 to 16 +/- 6 mm Hg (p less than 0.01). The 2 nonresponders had the largest left ventricular volumes on 2-dimensional echocardiograms. Responders were randomized to intermittent (16 hours/day) or continuous (24 hours/day) treatment for 1 month followed by a month of the alternate treatment. After 1 month of intermittent treatment, the hemodynamic response after reapplication was similar to the initial response. After another month of continuous treatment, hemodynamic values 24 hours after application were similar to initial control values and there was no change after removal and reapplication. Thus, the moderate vasodilator effect of transdermal nitroglycerin in CHF is maintained with intermittent treatment, whereas tolerance develops with continuous treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103412     DOI: 10.1016/0002-9149(87)91115-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Mechanisms of nitrate tolerance: a review.

Authors:  R J Katz
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

2.  Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure.

Authors:  J A Bauer; J P Balthasar; H L Fung
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

3.  Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.

Authors:  G L Bartels; W J Remme; A C Wiesfeld; F J Kok; M P Look; X H Krauss; H A Kruyssen
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

4.  The role of nitric oxide in heart failure. Potential for pharmacological intervention.

Authors:  P Macdonald; C Schyvens; D Winlaw
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

Review 5.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 6.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 8.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 9.  Nitrates in congestive heart failure.

Authors:  J Dupuis
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

10.  Haemodynamic effects of glyceryl trinitrate following repeated application of a transdermal delivery system with a phasic release profile.

Authors:  A Wiegand; R Bonn; F Wagner; D Trenk; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.